MyFinsight
Home
Compare
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
|
Compare
Income Overview
Net Income
-$159,393K
EPS
-$1.44
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
Research and development
48,665
41,484
29,416*
General and administrative
26,412
17,736
12,161*
Total operating expenses
75,077
59,220
41,577
Loss from operations
-75,077
-59,220
-41,577*
Interest income
3,587
3,457
2,740*
Interest expense
1,233
1,245
1,371*
Foreign exchange loss, net
-32
-44
-33*
Change in fair value of 2022 usd financing warrants
86,231
20,046
5,708*
Gain on extinguishment of contribution payable
-
-
0*
Total other income/(expense)
-83,909
-17,878
-4,371*
Net loss
-158,986
-77,098
-45,948*
Unrealized gain/(loss) on investments
-406
-262
83*
Loss on foreign currency translation
-1
1
-16*
Comprehensive loss
-159,393
-77,359
-45,882
Basic EPS
-1.44
-0.71
-0.514
Diluted EPS
-1.44
-0.71
-0.514
Basic Average Shares
110,684,720
108,790,941
89,327,608
Diluted Average Shares
110,684,720
108,790,941
89,327,608
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Comprehensive loss
-$159,393K
Net loss
-$158,986K
Unrealized gain/(loss) on
investments
-$406K
Loss on foreign
currency translation
-$1K
Total other
income/(expense)
-$83,909K
Loss from operations
-$75,077K
Interest income
$3,587K
Change in fair value of
2022 usd financing...
$86,231K
Total operating
expenses
$75,077K
Interest expense
$1,233K
Foreign exchange loss,
net
-$32K
Research and development
$48,665K
General and
administrative
$26,412K
Buy us a coffee
Definium Therapeutics, Inc. (DFTX)
Definium Therapeutics, Inc. (DFTX)